Lilly announces new science VP and research president
This article was originally published in Scrip
Lilly's executive vice–president of science and technology and president of Lilly research laboratories, Dr Steven Paul, is to retire from the company in February 2010. Dr Paul joined Lilly in 1993 and has also worked as vice–president of central nervous system discovery research and decision-phase medical research, and vice–president of therapeutic area discovery research and clinical investigation at the company. Before joining Lilly, he served as scientific director at the National Institute of Mental Health. Dr Paul will be succeeded by Dr Jan Lundberg, who has just stepped down as executive vice–president and head of global discovery research at AstraZeneca. He has been succeeded at AstraZeneca by Christer Köhler, head of global discovery for central nervous system and pain control, who has been has been appointed interim leader of discovery research until a permanent successor is found.
You may also be interested in...
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).